Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
About this item
Full title
Author / Creator
Hong, David S. , Kang, Yoon-Koo , Borad, Mitesh , Sachdev, Jasgit , Ejadi, Samuel , Lim, Ho Yeong , Brenner, Andrew J. , Park, Keunchil , Lee, Jae-Lyun , Kim, Tae-You , Shin, Sangjoon , Becerra, Carlos R. , Falchook, Gerald , Stoudemire, Jay , Martin, Desiree , Kelnar, Kevin , Peltier, Heidi , Bonato, Vinicius , Bader, Andreas G. , Smith, Susan , Kim, Sinil , O’Neill, Vincent and Beg, Muhammad S.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours.
Methods
Adults with various solid tumours refractory to standard treatments were enrolled in 3...
Alternative Titles
Full title
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Authors, Artists and Contributors
Author / Creator
Kang, Yoon-Koo
Borad, Mitesh
Sachdev, Jasgit
Ejadi, Samuel
Lim, Ho Yeong
Brenner, Andrew J.
Park, Keunchil
Lee, Jae-Lyun
Kim, Tae-You
Shin, Sangjoon
Becerra, Carlos R.
Falchook, Gerald
Stoudemire, Jay
Martin, Desiree
Kelnar, Kevin
Peltier, Heidi
Bonato, Vinicius
Bader, Andreas G.
Smith, Susan
Kim, Sinil
O’Neill, Vincent
Beg, Muhammad S.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7251107
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7251107
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-020-0802-1
